The stock of Madrigal Pharmaceuticals Inc (MDGL) has gone down by -14.55% for the week, with a -10.58% drop in the past month and a 28.00% rise in the past quarter. The volatility ratio for the week is 9.01%, and the volatility levels for the past 30 days are 4.89% for MDGL. The simple moving average for the past 20 days is -11.77% for MDGL’s stock, with a 5.10% simple moving average for the past 200 days.
Is It Worth Investing in Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Right Now?
The stock has a 36-month beta value of -0.37. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 4 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MDGL is 18.39M, and at present, short sellers hold a 22.33% of that float. On January 15, 2025, the average trading volume of MDGL was 434.10K shares.
MDGL) stock’s latest price update
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)’s stock price has dropped by -9.74 in relation to previous closing price of 303.70. Nevertheless, the company has seen a loss of -14.55% in its stock price over the last five trading days. fool.com reported 2025-01-13 that Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday.
Analysts’ Opinion of MDGL
Wolfe Research, on the other hand, stated in their research note that they expect to see MDGL reach a price target of $382. The rating they have provided for MDGL stocks is “Outperform” according to the report published on June 11th, 2024.
BofA Securities gave a rating of “Underperform” to MDGL, setting the target price at $150 in the report published on April 22nd of the previous year.
MDGL Trading at -13.67% from the 50-Day Moving Average
After a stumble in the market that brought MDGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.57% of loss for the given period.
Volatility was left at 4.89%, however, over the last 30 days, the volatility rate increased by 9.01%, as shares sank -9.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.95% upper at present.
During the last 5 trading sessions, MDGL fell by -14.55%, which changed the moving average for the period of 200-days by +5.92% in comparison to the 20-day moving average, which settled at $310.70. In addition, Madrigal Pharmaceuticals Inc saw -11.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDGL starting from CRAVES FRED B, who sale 3,600 shares at the price of $315.31 back on Dec 03 ’24. After this action, CRAVES FRED B now owns 11,000 shares of Madrigal Pharmaceuticals Inc, valued at $1,135,122 using the latest closing price.
CRAVES FRED B, the Director of Madrigal Pharmaceuticals Inc, sale 3,400 shares at $350.30 during a trade that took place back on Nov 25 ’24, which means that CRAVES FRED B is holding 14,600 shares at $1,191,028 based on the most recent closing price.
Stock Fundamentals for MDGL
Current profitability levels for the company are sitting at:
- -7.06 for the present operating margin
- 0.96 for the gross margin
The net margin for Madrigal Pharmaceuticals Inc stands at -6.69. The total capital return value is set at -0.61. Equity return is now at value -129.76, with -79.11 for asset returns.
Based on Madrigal Pharmaceuticals Inc (MDGL), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.62. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -36.19.
Currently, EBITDA for the company is -379.97 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 75.6. The receivables turnover for the company is 2.55for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.98.
Conclusion
To sum up, Madrigal Pharmaceuticals Inc (MDGL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
